Session » Poster Session 3
The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.
Date: Saturday, May 2, 2020
Time: 4:15PM-5:15PM
- 4:15PM-5:15PM
-
Abstract Number: 165
A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus
- 4:15PM-5:15PM
-
Abstract Number: 188
A New Multidisciplinary Pediatric SLE Clinic in a Large Urban Care Center: Feasibility, Patient Satisfaction, and Quality After One Year
- 4:15PM-5:15PM
-
Abstract Number: 184
A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents
- 4:15PM-5:15PM
-
Abstract Number: 119
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
- 4:15PM-5:15PM
-
Abstract Number: 186
Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases
- 4:15PM-5:15PM
-
Abstract Number: 145
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
- 4:15PM-5:15PM
-
Abstract Number: 163
Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies
- 4:15PM-5:15PM
-
Abstract Number: 130
Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis
- 4:15PM-5:15PM
-
Abstract Number: 115
Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study
- 4:15PM-5:15PM
-
Abstract Number: 160
CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis
- 4:15PM-5:15PM
-
Abstract Number: 120
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
- 4:15PM-5:15PM
-
Abstract Number: 148
Chronic Fatigue Symptoms in Children with Abrupt Early-onset OCD And/or PANS
- 4:15PM-5:15PM
-
Abstract Number: 132
Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit
- 4:15PM-5:15PM
-
Abstract Number: 183
Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship
- 4:15PM-5:15PM
-
Abstract Number: 126
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
- 4:15PM-5:15PM
-
Abstract Number: 141
Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review
- 4:15PM-5:15PM
-
Abstract Number: 127
Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus
- 4:15PM-5:15PM
-
Abstract Number: 121
Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis
- 4:15PM-5:15PM
-
Abstract Number: 113
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
- 4:15PM-5:15PM
-
Abstract Number: 134
Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus
- 4:15PM-5:15PM
-
Abstract Number: 193
Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE
- 4:15PM-5:15PM
-
Abstract Number: 168
Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
- 4:15PM-5:15PM
-
Abstract Number: 144
Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis
- 4:15PM-5:15PM
-
Abstract Number: 147
Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD
- 4:15PM-5:15PM
-
Abstract Number: 117
Family Impact of Juvenile Localized Scleroderma
- 4:15PM-5:15PM
-
Abstract Number: 125
Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis
- 4:15PM-5:15PM
-
Abstract Number: 181
Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis
- 4:15PM-5:15PM
-
Abstract Number: 146
Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
- 4:15PM-5:15PM
-
Abstract Number: 143
Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease
- 4:15PM-5:15PM
-
Abstract Number: 161
Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States
- 4:15PM-5:15PM
-
Abstract Number: 189
Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic
- 4:15PM-5:15PM
-
Abstract Number: 180
Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
- 4:15PM-5:15PM
-
Abstract Number: 159
Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis
- 4:15PM-5:15PM
-
Abstract Number: 123
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
- 4:15PM-5:15PM
-
Abstract Number: 167
Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment
- 4:15PM-5:15PM
-
Abstract Number: 118
Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers
- 4:15PM-5:15PM
-
Abstract Number: 137
Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
- 4:15PM-5:15PM
-
Abstract Number: 162
Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)
- 4:15PM-5:15PM
-
Abstract Number: 114
Musculoskeletal Ultrasound Study in Childhood Arthritis: A Limited Examination
- 4:15PM-5:15PM
-
Abstract Number: 182
Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood
- 4:15PM-5:15PM
-
Abstract Number: 179
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
- 4:15PM-5:15PM
-
Abstract Number: 139
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
- 4:15PM-5:15PM
-
Abstract Number: 190
Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
- 4:15PM-5:15PM
-
Abstract Number: 116
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
- 4:15PM-5:15PM
-
Abstract Number: 133
Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting
- 4:15PM-5:15PM
-
Abstract Number: 187
Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings
- 4:15PM-5:15PM
-
Abstract Number: 185
pGALS Training Increases Canadian and Kenyan Physicians’ Confidence in Examining the Musculoskeletal System in Children
- 4:15PM-5:15PM
-
Abstract Number: 124
Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic
- 4:15PM-5:15PM
-
Abstract Number: 131
Practice Patterns for Consulting Pediatric Rheumatology in a Large Pediatric Intensive Care Unit
- 4:15PM-5:15PM
-
Abstract Number: 128
Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
- 4:15PM-5:15PM
-
Abstract Number: 136
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
- 4:15PM-5:15PM
-
Abstract Number: 129
Reproductive Health Concerns in Young Adults with Pediatric Onset Rheumatic Diseases
- 4:15PM-5:15PM
-
Abstract Number: 166
Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
- 4:15PM-5:15PM
-
Abstract Number: 138
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
- 4:15PM-5:15PM
-
Abstract Number: 140
Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade
- 4:15PM-5:15PM
-
Abstract Number: 192
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
- 4:15PM-5:15PM
-
Abstract Number: 122
Systemic Inflammation and Cognitive Dysfunction in jSLE Patients
- 4:15PM-5:15PM
-
Abstract Number: 164
The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants
- 4:15PM-5:15PM
-
Abstract Number: 135
Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression
- 4:15PM-5:15PM
-
Abstract Number: 191
Utilization of Telemedicine in Pediatric Rheumatologic Care
- 4:15PM-5:15PM
-
Abstract Number: 142
WITHDRAWN